Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940

Pubmed ID

26726940

DOI

10.1038/bmt.2015.295

Author List

Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC

Authors

Ehab L. Atallah MD Associate Professor in the Medicine department at Medical College of Wisconsin
Karen-Sue B. Carlson MD, PhD Assistant Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin
Laura Michaelis MD Associate Professor in the Medicine department at Medical College of Wisconsin
Marcelo C. Pasquini MD, MS Associate Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-84953295752   4 Citations

MESH terms used to index this publication - Major topics in bold

Allografts
Female
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation
Humans
Male
Middle Aged
Primary Myelofibrosis
Pyrazoles
jenkins-FCD Prod-332 f92a19b0ec5e8e1eff783fac390ec127e367c2b5